

Coding Options for Administration of Autologous CAR-T as of April 2019

Autologous CAR-T Product Reporting Options ^A	Inpatient Facility Reporting					Outpatient Facility Reporting				
	Revenue Code*	Notes	HCPCS Code**	HCPCS Product Code Description	Payment Implications	Revenue Code*	Notes	HCPCS Code	HCPCS Product Code Description	Payment Implications
PRODUCT REPORTING TO MEDICARE	0891 - Special Processed Drugs - FDA Approved Cell Therapy	The charge for the product/drug is <u>typically</u> reported <u>without</u> a HCPCS code under revenue code 0250.	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Inpatient facility payment is considered inclusive of product costs. Product charges are used to determine NTAP and outlier payments, and are used in future rate-setting.	0891 - Special Processed Drugs - FDA Approved Cell Therapy	Report appropriate HCPCS code for the product	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	HCPCS product code generates ASP + 6% reimbursement
			Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, and dose preparation procedures, per therapeutic dose				Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, and dose preparation procedures, per therapeutic dose	
PRODUCT REPORTING TO MEDICAID***	0891 - Special Processed Drugs - FDA Approved Cell Therapy	The charge for the product/drug is <u>typically</u> reported <u>without</u> a HCPCS code under revenue code 0250 on inpatient claims but <u>with</u> a HCPCS code under revenue code 0636.	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Depends on the Medicaid Program	0891 - Special Processed Drugs - FDA Approved Cell Therapy	Report appropriate HCPCS code for the product	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Depends on the Medicaid Program
			Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, and dose preparation procedures, per therapeutic dose				Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, and dose preparation procedures, per therapeutic dose	
PRODUCT REPORTING TO COMMERCIAL PAYERS	0891 - Special Processed Drugs - FDA Approved Cell Therapy	The charge for the product/drug is <u>typically</u> reported <u>without</u> a HCPCS code under revenue code 0250 on inpatient claims but <u>with</u> a HCPCS code under revenue code 0636.	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Depends on commercial contracts or out-of-network payment	0891 - Special Processed Drugs - FDA Approved Cell Therapy	Report appropriate HCPCS code for the product	Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Depends on commercial contracts or out-of-network payment
			Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, and dose preparation procedures, per therapeutic dose				Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, and dose preparation procedures, per therapeutic dose	

^A The Medicare Special Edition article SE19009 published May 28, 2019 updates information in the April 2019 OPPS Update Transmittal 4255 released by CMS on March 15, 2019 and can be found at <https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/SE19009.pdf>. It also describes new value code 86 that providers may use to report their product acquisition cost. CMS gives providers the option to include cell collection and cell processing charges with the product charge and report all under revenue code 0891.

* Starting April 1, 2019, a new revenue code series, 089x (which is an extension of pharmacy 025x or 063x) should be used to report special processed drugs - FDA approved cell therapy and includes CAR-T cell products; see the National Uniform Billing Committee (NUBC) manual for more details: <http://www.nubc.org/subscribersonly/PDFs/Cell%20Therapy%20Changes%20August%202018.pdf>; All providers and payers have to use the new codes per the HIPAA transaction code set regulation.

**HCPCS codes do not typically print on inpatient Medicare claims so the product Q-codes, Q2041 and Q2042 are not expected to appear on Medicare inpatient claims despite the codes being shown here unless Medicare instructs differently.

***Determine specifics of reporting requirements from your state's Medicaid program and the specific patient's Medicaid plan.

DISCLAIMER: This information was obtained from third-party sources and is subject to change at any time without notice, including as a result of changes in coding, reimbursement, laws, regulations, rules, and policies. Content is informational only, and does not cover all situations or all payers' rules or policies. This document represents no promise or guarantee by ASBMT regarding coverage or reimbursement. The ultimate responsibility for coding and claims submissions lies with the physician, clinician, hospital, and/or other facility. Providers should consult their payers and check bulletins, manuals, program memoranda, and guidelines to ensure compliance with requirements.

DRAFT